Skip to main content
BAK and NOXA Are Critical Determinants of Mitochondrial Apoptosis Induced by Bortezomib in Mesothelioma
Published Web Location
http://europepmc.org/articles/PMC3676324?pdf=renderNo data is associated with this publication.
Abstract
Based on promising preclinical efficacy associated with the 20S proteasome inhibitor bortezomib in malignant pleural mesothelioma (MPM), two phase II clinical trials have been initiated (EORTC 08052 and ICORG 05-10). However, the potential mechanisms under
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.